Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine + cisplatin vs placebo plus gemcitabine + cisplatin in first-line advanced biliary tract cancer
2018-004688-30Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer and cholangiocarcinoma (CCA) comparing Durvalumab + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Primary endpoint: Overall survival. Started Apr 2019; status: active.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2018-004688-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004688-30.